Filing Flows › Arcadia Biosciences (RKDA) › Q1 2026
Arcadia Biosciences (RKDA) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 14, 2026
Arcadia Biosciences (RKDA) reported revenue of $1.1M for the first quarter 2026 (Q1 2026), -8% from a year earlier and +22% from the quarter before. Operating margin was -70.8%, net loss $4.4M (398.6% of revenue).
Arcadia Biosciences, Q1 2026: revenue $1.1M (-8% year over year), operating margin -70.8%, net loss $4.4M, operating cash flow −$1.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.1M | +22% | -8% |
| Operating profit | −$779K | — | -247% |
| Net earnings | −$4.4M | — | -269% |
| Operating cash flow | −$1.1M | — | — |
What changed
Revenue was $1.1M in Q1 2026, down 8% year over year and up 22% from the previous quarter.
Operating costs exceeded revenue by $779K, an operating margin of -70.8%. Total costs grew 180% against a revenue fall of 8%. The quarter ended with a net loss of $4.4M, wider than the previous quarter's $1.3M loss. Net interest and other expense of $3.6M was the main reason.
Operating cash flow was −$1.1M. Non-cash charges added back $8K of depreciation and $15K of share-based compensation. Working capital and other items added $3.3M.
Questions
What was Arcadia Biosciences' revenue in the first quarter 2026?
Arcadia Biosciences (RKDA) reported revenue of $1.1M for the first quarter 2026 (Q1 2026), -8% from a year earlier and +22% from the quarter before.
Was Arcadia Biosciences profitable in the first quarter 2026?
Operating loss was $779K (-70.8% of revenue) and net loss $4.4M.